# Pharmacokinetics and Safety of Fevipiprant in Patients With Renal Impairment Compared to Matched Healthy Subjects

> **NCT03087942** · PHASE1 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 45 (actual)

## Conditions studied

- Renal Insufficiency

## Interventions

- **DRUG:** QAW039
- **DRUG:** QAW39A
- **DRUG:** QAW39A2107
- **DRUG:** QAW39A2107

## Key facts

- **NCT ID:** NCT03087942
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-07-05
- **Primary completion:** 2018-08-07
- **Final completion:** 2018-08-07
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2020-12-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03087942

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03087942, "Pharmacokinetics and Safety of Fevipiprant in Patients With Renal Impairment Compared to Matched Healthy Subjects". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03087942. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*